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Abstract 
Background:   
Infections post cardiac surgery can have potentially devastating consequences. Adequate 
antimicrobial prophylaxis is therefore crucial to limit the occurrence of such complications. 
Cefazolin is a commonly prescribed prophylactic agent for major cardiac surgery requiring 
cardiopulmonary bypass (CPB). The effects of CPB on the pharmacokinetic profile of 
cefazolin are largely unknown. To date there is no published work determining the optimal 
bolus dosing of cefazolin required to achieve acceptable concentrations intra-operatively 
during and post CPB. 
Aim:  
The aim of this study was to describe the total serum cefazolin levels during elective valve 
replacement surgery on CPB at CMJAH. 
Method: 
A prospective, contextual, descriptive design was used in this study. Cefazolin plasma 
concentrations were analysed at specific pre-determined time intervals in adults patients 
scheduled for elective valve replacement surgery. Convenience sampling was used. 
Results:   
Sixteen patients were enrolled in the study with equal number of males and females, 
ranging from 18 years to 59 years of age and with a mean BMI of 28.2 kg/m² (range of 18.1 
to 40.2 kg/m²). The mean trough for the unbound concentration of cefazolin was 5.02 
µg/ml (range of 2.79 to 10.35 µg/ml). For 5 out of the 16 patients (31.25%) the targeted 
therapeutic goal of time above MIC (4 µg/ml) of 100% (T > MIC 100%) was not achieved. 
Seven corresponding pre and post CPB serum samples (A1-A7) were statistically analysed 
using the paired t-test. The results indicated no statistically significant differences between 
samples A1-A5 (p = 0.11, 0.34, 0.46, 0.32 and 0.98 respectively). There was a statistically 
significant difference between the samples A6 and A7 (p = 0.024 and 0.025), however, the 
clinical significance of these small differences is questionable. 
Conclusion:   
Surgical site infections not only result in significant morbidity and mortality but also lead to 
an increased financial burden to the country’s economy. This study has shown that 
potentially 31.25% of the patients undergoing cardiac surgery may have an increased risk 
of acquiring infections due to sub-optimal levels of prophylactic antibiotic during the 
surgery. In addition, the findings point towards no sequestration of cefazolin in the CPB 
circuits. 
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Chapter 1: Overview of study 
 
1.1 Introduction 
Post-surgery the occurrence of surgical sites infections (SSIs) is always a concern, largely 
due to the morbidity and mortality associated with such infections. In the past SSI was 
thought to be primarily linked to the surgical team, however the impact of implementing 
other multi-disciplinary strategies is significant in minimising the incidence of SSI (1). A 
recent study demonstrated that among the nosocomial infections, SSIs are the most 
common having an incidence of 38% of all hospital acquired infections (HAIs) (2). Following 
cardiac surgery with cardiopulmonary bypass (CPB), SSIs, although rare, may occur in the 
lower limbs (venous graft site) or more worryingly involve the sternum, with devastating 
consequences. 
The incidence of sternal wound infection (SWI) in the literature ranges from 0.5% to 10% 
(1, 3-10). Deep SWI (mediastinitis) has an incidence of 0.4% to 5% and is associated with a 
substantive morbidity and mortality, which may be up to 47% (3). Moreover, the associated 
treatment cost is a massive burden to the public health sector and as such antibiotic 
prophylaxis is imperative for CPB surgery (5). Cefazolin, a first generation cephalosporin, is 
generally considered to be an appropriate prophylactic antibiotic agent to reduce the 
impact of SSI post CPB surgery. However, there is a substantial variation in the precise 
regimen prescribed at various institutions globally (11). 
 
1.2 Background 
Current regimens for prophylaxis in CPB surgery were developed from empiric studies that 
observed post-operative infection reduction in both cardiac and non-cardiac surgeries. The 
current practice at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) consists of 
two grams of intra-venous (IV) cefazolin given at the induction of anaesthesia, with a repeat 
dose every four hours intra-operatively, taking into account the half-life (t½) of cefazolin. 
This is similar to The Society of Thoracic Surgeons recommendation of administering two 
grams (adult above 60 kg) of cefazolin within one hour of the skin incision and a repeat of 
one gram every three to four hours until the end of surgery (11). However, Bratzler et al 
(12) recommended a single pre-incision dose of two grams of cefazolin in adult patients for 
cardiac surgery. The recommendation from the Australian guidelines for antibiotics 
prophylaxis in cardiac surgery is one gram (or two grams, if weight above 80 kg) at the 
induction of anaesthesia and thereafter eight hourly for a further two doses (13). In South 
Africa, the South African Antibiotic Stewardship programme (14) recommends a single dose 
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of two grams of cefazolin given pre-operatively for cardiothoracic surgery and a repeat 
dose given should the surgery be prolonged or associated with severe blood loss. 
Additionally, there are some institutions that routinely administer a repeat dose upon 
completion of CPB, their rationale is to compensate for the losses that may occur in the 
CPB circuit (15). In light of the above discrepancy, it is unclear whether adequate cefazolin 
blood concentrations are produced with any of the regimens described. It is a concern that 
the presence of the CPB circuit may modify antibiotic levels in the patient, taking into 
consideration the vast physiological changes associated with CPB. 
A literature review with regards to the serum cefazolin levels during CPB surgery yielded 
only three studies. Hutschala at al (3) investigated the extent of cefazolin penetration into 
soft tissue during cardiac surgery using in vivo microdialysis. The authors concluded that 
the interstitial tissue concentrations of cefazolin were within therapeutic range for the 
prevalent pathogens causing SWIs. However, this was achieved by using a higher dose of 
four grams of cefazolin before skin incision and a further two grams during skin closure. 
This practice is not in line with national or international recommendations and guidelines 
as the dose is higher than conventionally prescribed (11, 13). Theoretically this increases 
the risk of side effects. 
Fellinger et al (16) did a pilot study to measure the serum levels of cefazolin during CPB 
surgery. The results showed serum levels of cefazolin remaining above MIC90 (Minimum 
inhibitory concentration at 90% inhibition) for only two pathogens. These were 
Staphylococcus aureus and Staphylococcus epidermidis and the serum levels of cefazolin 
were below MIC90 for all other prevalent pathogens.  
Adembri et al (15) compared a bolus and continuous infusion of cefazolin in patients 
undergoing elective cardiac surgical procedures. The authors concluded that 90% of the 
patients in the continuous infusion group had a plasma level above MIC90 throughout 
surgery compared with the bolus group where this goal was only achieved for 30% of the 
group. 
The influence of the CPB circuit amongst the bolus regimens that are currently in vogue 
needs to be ascertained first. Further research regarding continuous infusion regimens is 
also required as currently they are not recommended by any national or international 
guidelines. The lack of evidence based prophylaxis guidelines and the potential for 
prophylaxis failure in the bolus group results in a dilemma regarding what constitutes 
appropriate antibiotic prophylaxis in cardiac surgery. 
In addition, Mets (17), in a review article detailed the effects of CPB on the 
pharmacokinetics of numerous commonly used anaesthetic drugs including induction 
agents, volatiles, opioids, muscle relaxants and antibiotics. He described the 
pharmacokinetic changes of cefazolin demonstrating a discontinuity from the normal decay 
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profile with a sudden decrease in plasma level coinciding with the initiation of CPB. The 
review failed to address the therapeutic implications of these changes (17). 
 
1.3 Problem statement 
There is paucity of literature pertaining to the pharmacokinetics of prophylactic antibiotics 
due to the physiological changes that occur during CPB. Little is known about the altered 
volume of distribution, from the circuit itself, the large volume of intravenous fluids 
(cardioplegia) used intra-operatively, actual antibiotic concentration during CPB, the aortic 
cross clamp time and the opposing effects of hypothermia and systemic inflammatory 
response syndrome (SIRS) on renal clearance. 
Understanding the distribution and kinetics of cefazolin during CPB is necessary to help 
further inform the discussion on this uncertain matter. If there is indeed sequestration of 
cefazolin in the CPB circuit (18), resulting in the patient’s serum concentration being below 
MIC90. The dosing regimen will need to be reconsidered and evaluated. 
Current practice at CMJAH is in alignment with the guidelines of the South African Antibiotic 
Stewardship Programme (14). It is not known if this practice does in fact provides adequate 
therapeutic levels of cefazolin prophylaxis to these patients. 
 
1.4 Aim and objectives  
1.4.1 Aim 
The aim of this study was to describe the total serum cefazolin levels during elective valve 
replacement surgery on CPB at CMJAH. 
 
1.4.2 Objectives 
The primary objectives of this study were to:  
• describe antibiotic levels in the patient’s serum before, during and after CPB  
• describe serial antibiotic levels in the circuits during the CPB period. 
The secondary objective of this study was to describe the pre-operative and intra-operative 
creatinine clearance. 
 
 
4 
 
1.5 Research assumptions  
The following definitions were used in this study. 
Adult patient: a patient between 18 and 60 years.  
CMJAH research group:  researchers from the cardiothoracic ICU at CMJAH. 
Burns Trauma Critical Care Research Centre (BTCCRC):  research centre based at the 
University of Queensland, Australia. 
 
1.6 Demarcation of study field  
The study was conducted in the adult cardiothoracic theatre at CMJAH in Johannesburg, 
South Africa. It is a 950 bed central hospital affiliated to the University of the 
Witwatersrand. CMJAH is an academic referral centre for cardiothoracic patients in the 
Gauteng province and on average 400 cardiothoracic cases on CPB are done annually. 
 
1.7 Research methodology  
A prospective, contextual, descriptive research design was used in this study.   
1.7.1 Study population  
The study population comprised patients undergoing elective valve replacement on CPB 
from the cardiothoracic unit at CMJAH.  
  
1.7.2 Study sample 
A sample size of 16 patients was determined for this study in consultation with the BTCCRC, 
and convenience sampling was used. Inclusion and exclusion criteria for this study were 
defined. 
 
1.7.3 Data collection  
This research project was a collaborative project between the CMJAH research group and 
the BTCCRC. 
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Prior to data collection all the relevant approvals were obtained and the research was 
carried out adhering to the principles of the Declaration of Helsinki, 2013 (19) and the South 
African Good Clinical Practice Guidelines (20). 
Data were collected by DC from the CMJAH research group, adhering strictly to the 
standard operating procedure for data collection.  
The samples were couriered to the BTCCRC by a specialised courier service where they 
were analysed in an accredited laboratory. 
 
1.7.4 Data analysis  
Data were captured and analysed on a Microsoft® Excel 2013 spreadsheet. Descriptive and 
inferential statistics were used for analysis. Paired T tests were used to compare the pre-
operative and intra-operative creatinine clearance and the pre and post CPB serum samples 
and a Kaplan Meier survival curve graphically represented the serial cefazolin levels. 
 
 1.8 Significance of the study  
The findings of this study will shed light on the pharmacokinetics of prophylactic antibiotics 
during CPB. The results may lead to a review of the existing antibiotic prophylaxis regimen 
at CMJAH. Following analysis of the blood samples for cefazolin levels, it will be known if 
the intra-operative serum concentrations are within the therapeutic range and therefore 
adequate to prevent SSIs or if the current regimen must be adjusted. 
 
1.9 Outline of research report 
The following chapters are presented in the research report. 
Chapter 1 Overview of study 
Chapter 2 Literature review 
Chapter 3 Research methodology 
Chapter 4 Results and discussion 
Chapter 5 Summary, limitation, recommendations and conclusion. 
 
 
 
1.10 Summary 
In this chapter an overview of the study was given. In the following chapter the literature 
review will be presented.  
6 
 
Chapter 2: Literature review 
 
2.1 Introduction 
Infections in cardiac surgery can have devastating outcomes in terms of morbidity and 
mortality. Antibiotic prophylaxis becomes crucial in order to limit these life threatening 
complications. But, with the additional effects of the aortic cross-clamp, hypothermia and 
the CPB circuit on the antibiotic, any deviation to the pharmacokinetic profile of the 
antibiotic is currently unknown. Little has been done linking the dosing of the antibiotic and 
its corresponding plasma level in this group of patients. In this chapter the need for 
antibiotic prophylaxis in cardiac surgery is highlighted, with particular focus on the 
pharmacokinetics of cefazolin. The literature review commences with a background of the 
problems, SSI, mediastinitis and the pathogenesis involved as well as elaborates on the 
resultant complications. The review then addresses antibiotic prophylaxis with reference 
to general principles and then specifically in cardiac surgery. Thereafter, the review 
examines the CPB machine followed by an overview of the physiological changes that 
occur. Finally, the discussion leads to the pharmacological properties of cefazolin, with 
emphasis on the pharmacokinetics.  
 
2.2 Background 
Joseph Lister at the Glasgow Royal Infirmary, originally introduced the principles of 
"antisepsis" in the late 1860’s. This led the way to radical changes in surgical procedures. 
He acknowledged the hypothesis of Louis Pasteur regarding microbiology and developed 
the concept of sterile surgery by introducing carbolic acid. Prior to this, up to 80% of surgical 
patients developed sepsis. Unfortunately, most did not understand the pathological cause 
and process of the infection and believed that the resulting deaths of these patients were 
incidental (21).  In this era, the common complications described post-surgery were pyrexia 
followed by purulent drainage from the incision site, profuse sepsis and often death. Even 
though Lister’s principles had drastically improved morbidity and mortality outcomes, 
purulent drainage from the incision site, now referred to as SSI, remains a devastating 
complication following surgery (3). 
 
2.3 Surgical site infection 
Previous studies cited urinary tract infection as the most common HAI. Lewis et al (2) 
performed a study using HAI surveillance data from 15 community hospitals participating 
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in the Duke Infection Control Outreach Network. It included complete hospital-wide and 
surgical surveillance data from January 1, 2010 to June 30, 2012. They found that SSIs were 
the most common of the nosocomial infections, accounting for 38% of all HAIs (2).  
In the past the main focus was on the surgical team to prevent SSIs. However, it has been 
shown that anaesthetists can also contribute in decreasing the incidence of SSIs both in the 
theatre and the critical care unit (1). 
The United States Centre for Disease Control and Prevention (CDC) developed the National 
Nosocomial Infections Surveillance system that classified SSIs into three categories:  
• superficial incisional SSI, limited to the skin and the underlying subcutaneous tissue 
• deep incisional SSI, comprising the facial layer and muscle  
• organ/space SSI, penetrating the deeper anatomical layers (22, 23). 
The three classifications are illustrated in Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Cross-section of abdominal wall depicting CDC Classification of SSI (22) 
 
The causative microbes leading to SSIs commonly originates from the patient’s endogenous 
flora. Most frequently cultured pathogens are Staphylococcus aureus, coagulase-negative 
Staphylococci, Enterococcus spp and Escherichia coli. The incidence of these microbes is 
specific to the surgical procedure as detailed in Table 2.1. (24) 
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Table 2.1 Pathogens commonly associated with different surgical procedures (24) 
 
 
 
 
 
 
 
 
 
 
SSIs are not only associated with a significant increase in morbidity and mortality, 
prolonged hospital stay, median increase of 14 days (25), but also with increased cost (26). 
The financial burden of SSI on the health care system is quite substantial and estimated to 
be around US$1 billion to US$10 billion each year in direct or indirect medical costs in the 
United States of America (27).  In a retrospective cohort study Perencevich et al (27), used 
patient questionnaires and administrative databases to assess the effect of SSIs, during the 
first eight weeks after being discharged. They found the incidence of SSI to be 1.9% (89 out 
of 4571 procedures) with a higher average medical expenditure for patients with SSI 
(US$5,155) than the patients without SSI (US$1,773). This translated to a resultant increase 
of 290% in cost. In addition patients with SSI used more healthcare resources, comprising 
mainly more homebased health aides, radiology, outpatient and emergency department 
visits. They also had a higher number of hospital readmissions (27). 
In cardiac surgery the SSI can occur from the leg (venous graft site), but more worryingly 
from the sternum which can lead to devastating consequences. 
 
2.4 Sternal wound infection 
SWI is an uncommon but potentially life threatening complication that often develops into 
mediastinitis. In order to access the heart and surrounding structures, a median 
sternotomy incision is commonly used for open cardiac surgery. The less common incision 
is the transverse sternotomy with bilateral thoracotomy (clamshell) required for the 
surgical excision of large tumours, severe traumatic chest injuries or in bilateral lung 
Type of surgery Common pathogens 
Cardiac Staphylococcus aureus, coagulase-negative 
Staphylococcus                                                                    
Neurosurgery Staphylococcus aureus, coagulase-negative 
Staphylococcus                                                                    
Breast Staphylococcus aureus, coagulase-negative 
Staphylococcus                                                                    
Ophthalmic Staphylococcus aureus, coagulase-negative 
Staphylococcus, streptococci, gram-negative 
bacilli                                                                  
Vascular Staphylococcus aureus, coagulase-negative 
Staphylococcus                                                                    
Gastrointestinal Gram-negative bacilli, anaerobes 
Gynaecological Gram-negative bacilli, anaerobes, enterococci, 
Group B Streptococci 
Urological Gram-negative bacilli 
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transplantation (28). The first median sternotomy was performed by Milton in 1897, to 
remove a tuberculous lymph node compressing the anterior mediastinum. However, his 
second case in 1901, demised from overwhelming sepsis after a foreign body was 
successfully removed from the patient’s trachea (29).  Although in 1953, Shumacker 
became the first surgeon to recommend a median sternotomy for elective heart surgery 
having successfully used it for a valvulotomy (29). It was only in 1957 that Julian and 
associates published a report of four patients requiring cardiac surgery where they avoided 
the bilateral anterior thoracotomy and used the median sternotomy (29). This surgical 
incision resulted in a marked reduction in operating time, an excellent global exposure of 
the heart and less pulmonary trauma making the median sternotomy what it is today (29-
31). 
With regard to sternal closure in low-risk patients, it is generally accomplished with simple 
closure. However, prophylactic sternal reinforcement techniques are used in most cases 
and these include: the common wiring technique (figure of 8, simple wires and the Robicsek 
weave) and rigid titanium plating with fixation of the sternum utilising screws (32). 
Although the wiring technique might be a more cost effective solution to sternal closure, 
in a prospective, randomized multicentre trial, Raman et al (33) have demonstrated that 
the mechanical benefits of the rigid plate fixation resulted in superior bone healing to that 
of common wiring, thereby improving morbidity. The subcutaneous tissues are typically 
closed with absorbable sutures and the skin closed in a subcuticular fashion (28).  
The incidence of SWI in the literature varies with a range of 0.5% to 10% (1, 3-10). Sharma 
et al (4), reviewed patients that had coronary artery bypass graft surgery retrospectively 
between June 1997 to December 2000 and found 122 among the 3443 patients (3.5%) 
developed SWI. 
SWI in the setting of cardiac surgery is not only a financial burden but increases morbidity 
and mortality. Various studies have highlighted multiple risk factors including diabetes, 
obesity, male gender, prolonged operative time, bilateral internal mammary artery grafts, 
post-operative transfusion, re-exploration for bleeding, renal insufficiency, chronic 
obstructive pulmonary disease, smoking, steroid use, peripheral vascular disease and 
prolonged mechanical ventilation. (5, 7, 9, 10, 34) 
There have been various attempts in the literature to classify SWI, based on the anatomy, 
onset and management and these are described below. 
El Oakley and Wright (5), classified mediastinitis in relation to the onset after surgery and 
the presence of risk factors. Whereas, Pairolero et al (35), describe their classification in 
chronological nature with regard to only the onset after surgery as displayed in Table 2.2. 
On the other hand, Jones et al (30) classified the wound in relation to the depth and tissue 
involvement, presented in Table 2.3, which was modified by Vlajcic et al (36), to include its 
resulting management.           
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Table 2.2 Pairolero’s (35) classification of SWI based on onset time 
                                                                                       
 
 
 
 
 
Table 2.3 Jones et al, (30) classification of SWI based on tissue involvement 
                                                  
 
 
 
 
 
 
 
 
 
 
 
However, to maintain consistency during data analysis, various reports have sub-divided 
SWI into two groups.  
• superficial SWI: infection limited to the skin and subcutaneous tissue 
• deep SWI: infection with sternal osteomyelitis with or without the involvement of 
the retrosternal space (mediastinitis) (5). 
 
 
Type Onset of infection 
I Occurs within first few 
days 
II Occurs within first few 
weeks 
III Occurs months to years 
later 
Type 
 
Depth Tissue involvement 
1a Superficial Skin and subcutaneous 
tissue dehiscence 
1 b Superficial Exposure of sutured 
deep fascia 
 
2a Deep Exposed bone, stable 
wired sternotomy 
 
2b Deep Exposed bone, unstable 
wired sternotomy 
3a Deep Exposed necrotic bone, 
unstable, heart exposed 
 
3b Deep Types 2 or 3 with sepsis 
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Mediastinitis 
To understand the relevance of mediastinitis, a review of the anatomy of the mediastinum 
is primordial. The mediastinum is the mass of tissue between the two pulmonary spaces in 
the thoracic cavity. It is enclosed by the pleura and houses all the thoracic viscera with the 
exceptions of the lungs. It originates from the superior thoracic inlet to the diaphragm, 
anteriorly it is housed within the sternum and costal cartilages to the thoracic vertebrae 
posteriorly as illustrated Figure 2.2 (37). The critical and vital organs in the mediastinum 
explains why mediastinitis is regarded as a life threatening complication of cardiac surgery. 
 
 
Figure 2.2  Anatomy of the mediastinum (37) 
 
Mediastinitis is an inflammation of the cellular tissue in the mediastinum (36). In cardiac 
surgery it is a complication of a progressing superficial SWI. Sexton (38) stated that 
historically, prior to cardiac surgery, mediastinitis resulted mainly from the proliferation of 
odontogenic or retropharyngeal infections and oesophageal perforation. The author also 
mentioned that rare causes of primary infections of the mediastinum were either from 
penetrating traumatic injuries or metastatic proliferation of infections. Furthermore Sexton 
(38) concluded that in modern practice, mediastinitis is more commonly attributed to a 
complication of cardiothoracic surgical procedures.  
Mediastinitis following cardiac surgery is an uncommon complication with an incidence 
rate between 0.4% to 5% reported in the literature (5). Tang et al (8) retrospectively 
reviewed 30102 cardiac surgical patients operated on between 1993 to 2003 and found an 
incidence of deep SWI of 0.77%. The authors also found a significantly higher mortality rate, 
three times more than in patients without mediastinitis. The mortality range documented 
in the literature varies from 14% to 47% following mediastinitis (5). Farinas et al (39) found 
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a mortality of 35% and two of the patients out of the 34 with mediastinitis (5.9%) develop 
chronic osteomyelitis of the sternum. 
El Oakley and Wright (5) classified mediastinitis with respect to the timing of onset and the 
risk factors present and this is tabulated in Table 2.4. 
 
Table 2.4 El Oakley and Wright’s (5) classification of mediastinitis in patients undergoing 
CPB 
Type Presentation 
Type 1 Mediastinitis developing within 2 weeks of 
surgery without any risk factors 
Type 2 Mediastinitis presenting at 2 to 6 weeks after 
surgery without any risk factors 
Type 3a Mediastinitis type 1 including one or more risk 
factors 
Type 3b Mediastinitis type 2 including one or more risk 
factors 
Type 4a Mediastinitis type 1, 2 or 3 after one failed 
therapeutic trial 
Type 4b Mediastinitis type 1, 2 or 3 after more than one 
failed therapeutic trial 
Type 5 Mediastinitis with initial presentation more than 
6 weeks after a surgical procedure 
 
Clinically, mediastinitis can follow a fulminant or subacute clinical course. Patients usually 
present with tachycardia, fever, chest pain, signs of SWI or purulent discharge from the 
mediastinal area with sternal instability (38). Farinas et al (39) found that sternal wound 
drainage and/or cellulitis were present in 29 of 34 patients (85%) with post-operative 
mediastinitis. Other clinical signs include oedema of the chest wall, crepitus and Hamman's 
sign (crunching sound on auscultation synchronous with the cardiac cycle) (38). Although 
signs of sternal wound infection can precede or follow the recognition of mediastinitis, 
fever and systemic symptoms are the main precursor (38). 
 
2.5 Pathological aspects of sternal wound infection 
Surgical contamination occurs in the peri-operative period. This is caused by the 
endogenous flora of the patient or the surgical team and the exogenous flora within the 
operating room.  
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The impact of endogenous flora is essential in understanding SWI. In the 1950s, it was 
hypothesised that endogenous Staphylococcus aureus was the primary cause of numerous 
SSIs. It was only in 1995 that Kluytmans et al (40) shed more light on the matter, following 
their study conducted in Netherlands. The study comprised of 1980 patients requiring 
cardiac surgery between 1988 and 1991. The authors concluded that nasal colonisation by 
Staphylococcus aureus was a risk factor for SWI. In their follow-up study, they concluded 
that peri-operative eradication of nasal flora using a mupirocin based nasal ointment 
significantly decreases the SSI rate in cardiothoracic surgery patients (41). 
The exogenous causes of the SSIs are either handborne or airborne. Lepelletier et al (42) 
described the two components of airborne contamination, firstly, the presence of 
microorganisms (air bio-contamination) and secondly inert particles (air contamination). 
The author further explained that these microorganisms mainly results from the common 
air flora (rarely pathogenic) and the symbiotic human flora released by individuals. The 
inert particles are released by individuals (cutaneous squamous cells, skin appendages, 
respiratory droplets, and droplet nuclei), and textiles (surgical team's clothes and operative 
field drapes). These amounts correspond not only to the number of individuals in the 
operating theatre but to their movements as well as the textile material worn (42). 
Nowadays, contamination by non-sterile material is becoming extremely rare due to 
stricter guidelines for the sterilisation and disinfection of materials, and also the increasing 
use of disposable sterile material (42). Other rare types of post-operative contamination 
are from the metastatic spread of infection occurring in the post-operative critical care unit 
(catheter bacteraemia or pneumonia) or by direct bacterial inoculation of the operative 
site during wound dressing (42). 
 
2.6 Microbiology 
Staphylococci species has been identified in multiple studies as the main pathogen 
responsible for post-operative SSIs. Their exact proportions do vary according to the 
reports (3, 4, 6, 30, 35, 42). Lepelletier et al (42) demonstrated that Staphylococcus aureus 
accounted for 40% to 60% of strains causing mediastinitis, closely followed by the 
coagulase-negative staphylococcus, involved in 20% to 30% of cases while the gram-
negative bacilli (Escherichia coli, Enterobacter, Klebsiella, Proteus, & Pseudomonas) 
comprise up to 20% of cases as described in Table 2.5 . 
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Table 2.5 Microbiology of mediastinitis (42) 
Microbiology of 
mediastinitis 
Percentage 
Gram-positive cocci  
Staphylococcus aureus 40% 
Coagulase-negative                                                                            
Staphylococcus 
30% 
Gram-negative bacilli  
Escherichia coli 5% 
Enterobacter spp. 10% 
Klebsiella spp. 3% 
Proteus spp. 2% 
Pseudomonas spp. 2% 
Other  
Candida < 2% 
Polymicrobial 10-40% 
 
2.7. Antibiotics 
The most common microorganisms causing SSIs from clean procedures are skin flora, 
including Staphylococcus aureus, Streptococcal species and coagulase-negative 
Staphylococci (43). It becomes essential to provide antibiotic prophylaxis against these 
pathogens, particularly in cardiac surgery, considering the devastating complications that 
may result from a SSI.  
Antibiotic prophylaxis constitutes a practice that potentially leads to the prevention of SSIs. 
Bratzler et al (12) sub-divided antibiotic prophylaxis into three broad categories: primary 
prophylaxis, secondary prophylaxis and eradication.  
According to Bratzler et al (12), primary prophylaxis points to the steps in the avoidance of 
acquiring a direct infection whereas secondary prophylaxis stands for the avoidance of 
recurrence or reactivation of a pre-existing infection. Eradication relates to the 
extermination of a colonized flora in order to avoid the proliferation of an infection (12). 
The necessity for the routine use of prophylactic antibiotics in a simple, clean surgical 
intervention such as inguinal hernia repair or breast surgery has been debated in the 
literature. Mazaki et al (44), in a double blind randomised control trial of prophylactic 
antibiotic versus placebo involving 200 patients undergoing open-mesh plug hernia repair, 
found the incidence of SSI to be 2% for the antibiotic group versus 13% for the placebo 
group. Additionally, it has been argued that whilst the relative risk of infection in cardiac 
surgery is small (0.4%-10%), the resulting SWI leading to severe morbidity and mortality, 
justifies the use of prophylactic antibiotics (43). 
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The optimisation of antibiotic prophylaxis requires that multiple factors be considered. 
These issues are discussed below. 
 
2.7.1 Preoperative-dose timing  
Previously the recommended time for administration of a prophylactic antibiotic was 
during the induction of anaesthesia. The optimal time for the administration of 
preoperative doses is deemed to be within 60 minutes prior to incision. However, some 
agents, e.g. vancomycin, requires infusion over one to two hours and this needs to be 
individualised (12).  
The latest recommendations by the Society of Thoracic Surgeons (45) encourage a 
continuation of prophylactic antibiotics for 48 hours or less. 
 
2.7.2 Obesity 
Multiple reports linked obesity with an increased risk for SSIs (5, 7, 10). The 
pharmacokinetics of antibiotics may be altered in this group of patients, therefore a dose 
adjustment based on body weight is often required (12). 
 
2.7.3 Intra-operative re-dosing 
There are instances for re-dosing to ensure therapeutic plasma and tissue concentrations 
of the antibiotic agent. These are the duration of the surgical procedure exceeding two 
half-lives of the drug and substantial blood loss occurring during the procedure (12). The 
half-lives of commonly used antibiotics in cardiac surgery are shown in Table 2.6.  
Table 2.6 Antibiotics half-life in adults with normal renal function (12) 
Antibiotic Half-life in adults with normal renal function 
(hours) 
Cefazolin 1.2-2.2 
Cefuroxime 1-2 
Erythromycin 3-5 
Clindamycin 2-4 
Gentamicin 2-3 
Vancomycin 4-8 
Ertapenem 3-5 
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2.7.4 Specific surgical procedure 
Depending on the common pathogens involved, there might be a need to use specific 
antibiotics as prophylaxis. For instance, in cardiac surgery, as mentioned earlier these 
microbes commonly are the skin flora (42, 43). However, for surgery involving a viscus, the 
pathogens consist of the endogenous flora inhabiting the specific viscus or that of the 
nearby mucosal surface. These resulting infections are usually poly-microbial and require 
alternative agents to be used as prophylaxis (12, 26, 42, 43). 
 
2.7.5 Pharmacokinetics 
Pharmacokinetics (PK) is defined as “the effects of the body on the drug’’ (46) or as stated 
by Roberts and Lipman (47), “Pharmacokinetics refers to the study of concentration 
changes of a drug over a given time period”. On the other hand, pharmacodynamics (PD) 
refers to the drug concentration and its resulting pharmacological effect (48) or simply ‘’the 
effect of the drug on the body’’ (46). The inter-relationship between PK and PD, illustrated 
in Figure 2.3, forms the basis of pharmacology. An understanding of these principles is 
essential to determine appropriate antibiotic dosing in order to achieve the desired clinical 
effect. 
 
Figure 2.3 The Relationship between pharmacokinetics and pharmacodynamics (49) 
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PK can be sub-divided into four major components: absorption, distribution, metabolism 
and excretion.  
Absorption 
During cardiac surgery, considering the drugs are intravenously administered, the principle 
of absorption becomes irrelevant as opposed to the other routes of drug delivery, where 
the percentage of the drug absorbed is variable, since the bioavailability of intravascularly 
administered drug is 100% (48).  
However, apart from route of administration there are numerous other factors altering 
drug absorption: “drug solubility, dissolution of the drug in a medium, nature of the vehicle 
dispersing the drug, concentration of drug, pH (for ionised drugs), circulation to the site of 
absorption and absorbing surface” (50).  
Distribution 
When giving a drug intravenously, its distribution throughout plasma and tissues can be 
likened to the process of dilution from the highly concentrated solution in the syringe to 
the less concentrated solution in plasma. This is due to the initial mixing of the drug into 
blood and being eventually transferred into tissues (51).  
Byer and Sarver (49) explained the two compartment PK model as the molecular transfer 
of a drug from the central compartment to the surrounding tissues. They further 
elaborated on the bi-directional nature of this process including the molecular transfer of 
the drug from the central compartment to the tissues and subsequently from the tissues 
to the central compartment, until an equilibrium is reached. This process of distribution 
typically follows a three-stage sequence as illustrated in Figure 2.4 (49).  Byer and Sarver 
(49) detailed the stage of distribution, which begins with the drug being absorbed into the 
systemic circulation. The net movement of the drug is initially from the plasma to the 
surrounding tissues. After the initial distribution equilibrium is achieved, the rate of 
transfer into the surrounding tissues is the same as the reverse transfer rate into the 
plasma, with no net molecular movement of drug. Following completion of the infusion, 
the plasma concentration of the drug begins to decrease more rapidly than that of the 
tissue concentrations. The tissues now serve as a drug reservoir, transporting the drug back 
into the plasma (49). 
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Figure 2.4 The stages of the distribution equilibrium (49) 
CP: plasma concentration; CT: tissue concentration; KT: rate constant.  
 
However, most drugs displays a more complicated three compartment PK model, as 
illustrated in Figure 2.5. The central compartment which is the plasma equilibrates with the 
rapidly and the slow equilibrating compartment. And this can be explained graphically by 
three phases of redistribution, rapid, intermediate and slow as shown in Figure 2.6.    
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Figure 2.5 The different compartment model (51) 
K10: Clearance; K12: rate constant for drug distribution from central compartment to rapidly equilibrating 
compartment; K13 rate constant for drug distribution from central compartment to slow equilibrating 
compartment; K21: rate constant for drug distribution from rapid equilibrating compartment to central 
compartment; K31: rate constant for drug distribution from slow equilibrating compartment to central 
compartment. 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 The three phases of redistribution (51) 
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Metabolism 
Byers and Sarver (49) defined metabolism as the process whereby multiple enzymatic 
reactions alter the chemical structure of the drug molecules. The authors further identified 
cytochrome P450 enzymes as the most significant class of enzyme and their function lies in 
the Phase I biotransformation of a number of drugs, which include: oxidation, reduction, 
hydrolysis and de-alkylation. This takes place mainly in the liver, although the 
gastrointestinal tract, lungs and to some degree the skin also have substantial levels of 
cytochrome enzymes (49). 
This transformation may be explained by the following three scenarios: 
Active drug  inactive metabolite 
Inactive drug  active metabolite 
Active drug  active metabolite. 
Phase 2 biotransformation: involves conjugation with glucuronic acid, acetate, amino acid 
or glutathione to facilitate the process of excretion in the urine or faeces (52).  
To summarise this process, hepatic metabolism involves structural alterations of the drug 
molecule to a form that is either lipophilic for excretion in the bile and eventually in the 
faeces, or a hydrophilic structure for excretion by the kidneys (53).  
Elimination 
Clearance (Cl) defined as the volume of blood from which a drug is withdrawn per unit of 
time, with unit ml/min, forms the basic principle in the process of elimination that occurs 
mainly in the liver and kidney (47). 
According to Shafer et al (51), hepatic Cl depends on the hepatic blood flow, enzyme 
activity and first pass effect for drugs administered orally. Hepatic Cl is equal to extraction 
ratio multiply by the liver blood flow. The resultant fat soluble drug and metabolite are 
excreted into the bile (51). 
Cl of hydrophilic drugs usually occurs via excretion into the urine. Renal clearance depends 
on the glomerular filtration rate, active tubular secretion and renal disease (51). 
 
2.7.5.1 Specific antibacterial pharmacokinetics 
The pharmacokinetics properties of antibacterials are more complex with multiple 
additional factors influencing the concentrations of these drugs at their target sites (47, 
54). These factors are discussed in the paragraph that follows. 
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Volume of distribution 
Volume of distribution (Vd) displays the relationship between the total amount of drug in 
the body and the plasma drug concentration. It is a mathematical hypothesis, which does 
not necessarily reflect a physiological or real space such as plasma or extracellular volume. 
Therefore the Vd of many drugs, specially highly lipophilic drugs, can be much higher than 
the total body water (49). Examples of hydrophilic antibiotics are β-lactams, 
aminoglycosides and glycopeptides which have a much lower Vd (<0.2 L/Kg) compared to 
the lipophilic antibiotics, fluoroquinolones, macrolides and tigecycline, which tend to have 
a substantially higher Vd (> 1 L/Kg) (46, 54). In the critically ill, there are further changes to 
Vd, these changes mainly affect the hydrophilic antibiotics (increase in Vd), whereby an 
increase in the loading dose may be warranted (54). 
Other factors influencing the Vd of a drug include: degree of ionisation, pKa (pH of a 
solution at which the ionised and unionised fraction of a drug is in equal amount), the size 
of the molecule and protein binding (52). Protein binding is predominantly with albumin 
(acidic and neutral drugs) and glycoprotein (basic drugs) (52, 55, 56).  
Clearance 
With regard to clearance of the drugs, it is either cleared by the kidney or liver. 
Hydrophilic antibiotics are predominantly cleared via renal clearance compared to 
lipophilic antibiotics which mainly involve hepatic clearance (54). 
Various factors affect Cl. An augmented renal clearance has been observed in critically ill 
patients without renal dysfunction (57-59). The patients with sepsis or increased 
inflammatory response often have higher than normal cardiac indices. Also in the absence 
of significant organ dysfunction there is often an increased renal preload and consequently 
increased drug clearance (47, 59). Declercq et al (60) found an augmented renal clearance 
in non-critically ill patients undergoing abdominal and trauma surgery, this phenomenon 
could easily be going on unnoticed during cardiac bypass surgery. With the compounding 
effect of the severe inflammatory response that occurs from the extracorporeal circuit 
there might be a significant increase in the renal clearance.  
Half-life 
t½ is defined as the time required for the plasma concentration of a drug to decrease by 
half (48). It is directly proportional to the Vd and inversely proportional to Cl, so the same 
factors that affect the changes in Vd and Cl will also significantly affect the t½ of the 
antibiotic (47). 
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Antimicrobial agents follow three modes of bacterial killing. 
Concentration-dependent killing with post-antibiotic effect 
The bacterial killing is proportional to maximal concentration (Cmax) attained compared to 
minimum inhibitory concentration (MIC) of targeted organism (Cmax/MIC). Therefore, only 
achieving most favourable killing once the maximal concentration passes a threshold peak 
to MIC ratio. Hence, the dosing goal is to enhance peak concentration of the antibacterial, 
e.g. aminoglycosides and fluroquinolones. (47, 53) 
Time-dependent killing 
In this pattern the bacterial killing is proportional to the extent of time the drug 
concentration is upheld above the MIC of the targeted organism (T > MIC). The goal of 
therapy is therefore to augment the duration of exposure by small dosing intervals, e.g. β-
lactams. (47, 53) 
Time-dependent killing with post-antibiotic effect 
The total drug exposure, also referred to as area under the curve (AUC), relative to MIC of 
the targeted organism is proportional to bacterial killing (AUC/MIC). The goal of therapy is 
therefore to augment the quantity of drug available via both dose and interval, e.g. 
vancomycin, clindamycin and linezolid. (47, 53) 
These three patterns are graphically represented in Figure 2.7(47).  
 
 
 
 
 
 
 
 
Figure 2.7 Pharmacokinetic and pharmacodynamics parameters of antibacterials (47) 
 
With regard to post-antibiotic effect, it represents the continued suppression of bacterial 
proliferation for an extended period after the antibiotic level drop below the MIC of the 
specific bacteria. Most antibacterials exhibit a post-antibiotic effect. β-Lactams 
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demonstrate very little post-antibiotic effect against gram-positive organisms, but no post-
antibiotic effect (with the exception of carbapenems) against gram-negative organisms, 
therefore the concentration of cefazolin has to be above MIC throughout the majority of 
the surgical procedure. However, aminoglycosides express a significant post-antibiotic 
effect of more than three hours (47). 
 
2.7.6 Cardiopulmonary bypass 
CPB was first used in 1953 by John Gibbon, Jr after 15 years of work in developing a machine 
with the capabilities of supporting respiration and providing an extracorporeal circulation. 
The goal of the extracorporeal circuit is to undertake four important vital functions: organ 
perfusion, systemic cooling and rewarming, respiratory functions, and optimisation of the 
surgical field by diverting blood from the heart during surgery. Deoxygenated venous blood 
is passively removed from the right atrium into a reservoir that additionally receives all 
blood suctioned during surgery, additional fluids, and drugs. Multiple factors determine the 
amount of venous blood drained from the heart and these are, the resistance in the venous 
circuit, the height from the patient to reservoir and central venous pressure. Leaving the 
reservoir, the blood is sieved of surgical debris and other contaminants via an arterial filter. 
It is then pumped to an oxygenator and heat exchanger unit before finally returning to the 
patient via the aortic cannula. The general components of the CPB circuitry is made up of 
a series of pumps and tubing for cardiotomy suction, bubble detectors, pressure monitors, 
venting and cardioplegia ports, and blood sampling ports including in-line blood gas 
analysers as described in Figure 2.8. (61, 62) 
 
Figure 2.8 Schematic representation of the CPB circuit (62) 
24 
 
Labelling of the components from Figure 2.8 are as follows: [1] integral cardiotomy reservoir; [2] membrane 
oxygenator; [3] venous blood line; [4] arterial blood line; [5] arterial filter purge line; [6] arterial line filter; [7] 
venous blood pump (also called the arterial pump head); [8] cardiotomy suction pump; [9] ventricular vent 
pump; [10] cardioplegia pump; [11] crystalloid cardioplegia; [12] water inlet line; [13] water outlet line; and 
[14] gas inlet line. (62) 
Depending on the surgical procedure, the type of CPB circuit used and cannulation sites 
may vary, however for the majority of elective cardiac procedures the full CPB circuitry is 
involved. There, blood is withdrawn from the right atrium and pumped back to the systemic 
and peripheral circulation via the aorta. Therefore, the CPB circuit takes over the complete 
function of the heart and lungs. (62)     
During CPB, there is a vast alteration in the PK principles. There is limited data in the 
literature to guide therapy whilst the PK changes from CPB are in effect. Shekar et al (18) 
reviewed the pharmacokinetics properties during extracorporeal membrane oxygenation 
and found lipophilic drugs such as fentanyl and midazolam to be highly sequestered. PK 
studies in neonates, have demonstrated increased Vd and decreased drug CL during extra 
corporeal membrane oxygenation (18).  
Miller et al (63) found a lower clearance of cefazolin during surgery (27.4 ml/min), 
compared to preoperative clearance (48.6 ml/min) and post-operative clearance (46.6 
ml/min). Since, cefazolin is up to 90% eliminated by the kidney, the clearance was 
representative of the renal clearance. The authors also found the decrease in cefazolin 
clearance constant throughout the surgery, including the duration of CPB. 
With regards to the pharmacokinetics of cefazolin during CPB surgery. From a pilot study 
in Vermont, USA  in 2002, Fellinger et al (16) measured the serum levels of cefazolin during 
CPB surgery. Their observations were that therapeutic range was only achieved for two 
pathogens involved, namely Staphylococcus aureus and Staphylococcus epidermidis. 
However, the protocol at their institution was to give one gram of cefazolin at onset of 
anaesthesia and an additional gram at the onset of CPB. Therefore it is not possible to 
extrapolate their findings to our practice, given the difference in both the dose and dosing 
frequency. 
Hutschala at al (3) in Austria, published in 2007, cefazolin penetration into soft tissue during 
cardiac surgery, using in vivo microdialysis. They found the median interstitial tissue 
concentration of cefazolin to be higher than the MIC90 for the prevalent pathogens involved 
in SWIs. The protocol used at their institution required four grams intravenous bolus before 
skin incision and a further two grams during skin closure. This is not a recommendation by 
any guidelines and therefore their findings cannot be extrapolated for any purposes. 
In Firenze, Italy, Adembri et al (15), in 2010 compared a bolus and continuous infusion of 
cefazolin in patients undergoing elective cardiac surgical procedures. They prospectively 
and randomly divided their 20 patients into either a bolus or a continuous infusion group. 
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The former group received two grams of cefazolin as a prophylaxis dose 30 minutes prior 
to surgical incision with additional doses of one gram at the end of CPB, as well as at nine 
and fifteen hours after CPB. The second group received a continuous infusion of initially 
two grams of cefazolin, followed immediately by an infusion of three grams at a rate of one 
gram every six hours. They demonstrated that 90% of the patients in the continuous 
infusion group were within therapeutic range throughout surgery compared to the bolus 
group where this goal was only achieved for 30% of the group. The authors concluded that 
continuous infusion exhibits pharmacokinetic and pharmacodynamic advantages 
compared to the bolus administration. However there is currently no additional evidence 
supporting the use of continuous infusions in prophylactic regimens. 
In a 2006 prospective study from Stanford University, California, Caffarelli et al (64) 
analysed the cefazolin serum levels of four groups of patients. Group A was the control 
group with 10 patients receiving cefazolin as antibiotic prophylaxis, undergoing vascular 
surgery with no CPB. Group B included 10 patients undergoing cardiac surgery with CPB 
time less than 120 minutes, Group C involved 10 patients where CPB time was more than 
120 minutes and Group D had 10 patients for cardiac surgery involving CPB and 
hypothermic circulatory arrest. The results showed that in all three groups on CPB, the 
serum cefazolin level was below the MIC90 for Staphylococcus aureus at various stages of 
surgery in the majority of the patients. The authors suggested increasing the initial dose 
from one gram to two grams of cefazolin at induction and to repeat a second dose after 
240 minutes. 
Bertholee et al (65) investigated the concentration of cefuroxime whilst on CPB and found 
that the current antibiotic regimen used (one and a half gram at onset of anaesthesia 
followed by one and a half grams at onset of CPB) did not maintain cefuroxime 
concentrations above the MIC throughout the operation. This translates to ineffective 
antibiotic prophylaxis. They concluded that further research with different antibiotic dosing 
regimens was therefore necessary to obtain adequate prophylactic levels. 
 
2.8 Cardiac surgery prophylactic antibiotics 
Cephalosporins form the core of standard prophylactic antibiotics for cardiac surgery owing 
to their low toxicity and broad microbial coverage. Current regimens for prophylaxis in CPB 
surgery were developed from studies that reviewed post-operative infection in both 
cardiac and non-cardiac surgeries (16). Engelman et al (11), in their report on antibiotic 
prophylaxis in cardiac surgery, singled out β-lactams as the antibiotics of choice, with the 
exception of specific population with high incidence of methicillin-resistant Staphylococcus 
aureus. 
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Bolon et al (66) performed a multi-institutional, international meta-analysis on 5761 
patients comparing the incidence of SSIs using a glycopeptide (vancomycin, teicoplanin) 
versus a β-lactams. The results showed that β-lactams were as effective as glycopeptides 
for the overall prevention of SSIs. Therefore, the authors recommended, based on 
availability and cost, the use cefazolin as standard cardiac surgery prophylaxis. Saginur et 
al (67), also concluded that cefazolin was a more effective prophylaxis and they did so 
following a multicentre double-blind randomized controlled trial comparing teicoplanin 
with cefazolin in elective cardiac surgery. 
Regarding gram-positive bacteria, the peptidoglycan layer (hence Penicillin binding protein, 
PBP) is positioned on the outer surface of the cell wall whereas for gram-negative bacteria 
a complex lipopolysaccharide structure is located on the outermost layer, therefore 
cephalosporins have to diffuse across the lipopolysaccharide membrane to reach the PBPs. 
The PBPs within each and every bacterium vary by type and amount. These targets are 
numbered by convention on the basis of molecular weight, with letters differentiating 
proteins of similar molecular weight. The events following the covalent binding of 
cephalosporins to the PBP targets that lead to cell lysis and death are not entirely 
understood (51, 68).  
Against gram-positive infections such as cellulitis, cefazolin remains a popular choice. This 
first generation cephalosporin is commonly used as part of home-based intravenous 
antibiotic programmes due to its relatively narrow spectrum, stability and side effects 
profile. In order to limit the rise of resistance and to decrease the growing antibiotic 
pressure, the use of a first generation cephalosporin is considered the sensible choice. (68) 
 
2.9 Pharmacological properties of cefazolin 
In order to maximise the efficiency of cefazolin as a prophylactic antibiotic and ensuring 
maximum time above MIC, knowledge of its specific pharmacology is of utmost 
importance. 
Cefazolin comes from the family of cephalosporin and is a first generation cephalosporin. 
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Figure 2.9 Chemical structure of cefazolin (69) 
 
Cephalosporins were first isolated from a filamentous fungus, known as cephalosporium. 
They were cultured from the sea near a Sardinian sewage outfall in 1945. Their molecular 
structure, illustrated in Figure 2.9, is closely related to that of penicillin. Since then, various 
semi-synthetic forms have been introduced. (70) 
Cephalosporin is considered to be bactericidal (69). They are usually well tolerated, but 
unfortunately do come with side-effects, such as injection site pain, allergic reactions of 
the penicillin type, hypotension, drowsiness, headache, weakness, hives, skin rashes, 
confusion and gastrointestinal upset. The overall cross-allergy between penicillins and 
cephalosporins involves around 10% of patients. The overall rate of unwanted skin 
reactions (urticarial rashes and pruritis) is quite rare and ranges between 1% and 3% (53). 
Pain may be experienced at intravenous or intramuscular sites of injection. If continued use 
for more than two weeks, reversible thrombocytopenia, haemolytic anaemia, neutropenia, 
interstitial nephritis or abnormal liver function tests may occur (53). 
Cefazolin’s mechanism of action is similar to that of other β-lactam drugs. Like the β-
lactams, cefazolin inhibits the bacterial cell wall synthesis. The peptidoglycan cross-linkage 
structure found within the bacterial cell wall is the primary target for these compounds. 
Peptidoglycans are made from cross-linked chains of polysaccharide consisting of 
alternating N-acetylglucosamine and N-acetylmuramic acid compounds resulting into a 
net-like structure. These structures via the action of several group of enzymes including 
transpeptidases, carboxypeptidases, and endopeptidases, are inserted into the bacterial 
cytoplasmic membrane. The lactam ring of the penicillins and cephalosporins has similar 
conformation to the terminal d-alanine-d-alanine of these pentapeptide enabling a 
covalent bond to be formed with these enzymes resulting in loss of enzyme activity. The 
enzyme drug targets are referred to as PBPs. (49) 
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2.9.1 Pharmaceutical properties 
Cefazolin (as sodium) presents in a 500 mg vial and a one gram vial, it is in a powdered form 
when reconstituted and diluted can be given either intramuscularly or intravascularly. The 
dosage ranges between 25 to 100 mg/Kg over 24 hours. This can be divided into three to 
four doses. The adult dose for surgical prophylaxis is one- two grams or 30 mg/kg as an 
intravenous bolus 30 to 60 minutes prior to surgical incision. (71, 72) 
Cefazolin is a polar, water-soluble compound, with a wide volume of distribution in the 
body (Vd of around 10L) which allows treatment of infection at most sites, including bone, 
soft tissue and muscle (56, 68, 70). 
Up to 90% of cefazolin is eliminated unchanged via the kidney. The elimination is more by 
glomerular filtration than by tubular excretion. It is between 75% to 90% plasma protein 
bound and this slows the glomerular filtration of the drug, resulting in a t½ of 1.5 to 2 hours, 
which allows 8 and 12-hourly dosing (55, 56, 68, 70, 73). Cefazolin binds to albumin on 
either the warfarin site or the bilirubin site or both (55). The percentage binding is lower 
with lower concentrations of albumin occurring with renal and hepatic dysfunction and 
displacement by acidic drugs such as salicylic acid, valproic acid and furosemide or 
endogenous substrates such as bilirubin and free fatty acids (55). A lower percentage 
binding will increase the free fraction of cefazolin with a resultant increase in its Vd. The 
increased free fraction of the drug will be eliminated more rapidly by the kidney (increased 
clearance with a decreased t½), requiring adjustments to both drug dosing and frequency 
to maintain therapeutic levels (59). 
 
2.10 Conclusion 
There are numerous and vastly contrasting practices in antibiotic prophylaxis. Variation 
exist not only in adult doses ranging from one gram up to four grams, but also in duration 
extending from single dose, 24 hour duration and up to 48 hour duration (3, 11, 16, 45). 
Some of these practices have been investigated and concluded that sub-therapeutic doses 
were used intra-operatively in cardiac surgery (16). The fact that the pharmacokinetic 
changes in CPB surgery remains fairly unexplored leaves an obvious gap. The CPB circuit is 
still, after more than 50 years of being in use, a foreign concept where many important 
properties are being simply left for speculation. The principle of augmented renal 
clearance, which occurs from SIRS, together with the decrease renal clearance that is seen 
in hypothermia, leads to more uncertainty regarding the pharmacokinetic of prophylactic 
antibiotics during CPB (47, 63). 
In view of all of the multiple confounding factors, it is difficult to predict the actual 
concentration of the drug that will reach the tissue site and if the actual concentration is 
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adequate for prophylaxis. Therefore, a study on the serum cefazolin levels during CPB 
surgery is vital to guide future acceptable prophylactic dosing strategies. 
 
2.11 Summary  
In this chapter a literature review was presented. In the following chapter the research 
methodology will be reviewed. 
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Chapter 3: Research methodology 
 
3.1 Introduction 
This chapter presents the problem statement, aim, objectives, ethical considerations, 
research methodology and the validity and reliability of this study.  
 
3.2 Problem statement 
Based on the South African Antibiotic Stewardship Programme guidelines (14), the current 
practice at CMJAH is to give a two grams bolus of cefazolin 30 minutes pre-operatively 
followed by a re-dose after four hours with prolonged surgery. The efficacy of this practice 
in achieving therapeutic levels of cefazolin intra-operatively cannot be confirmed due to 
paucity in the literature pertaining to the altered PK of antibiotics caused by the vast 
physiological changes that occur during cardiothoracic surgery and CPB.  
An understanding of the distribution and kinetics of cefazolin during CPB would therefore 
further inform this discussion. If there is indeed sequestration of cefazolin in the circuit 
(18), leading to concentrations below MIC90, then the dosing regimen will consequently 
require review. 
 
3.3 Aim and objectives  
3.3.1 Aim 
The aim of this study was to describe the total serum cefazolin levels during elective valve 
replacement surgery on CPB at CMJAH. 
 
3.3.2 Objectives 
The primary objectives of this study were to:  
• describe antibiotic levels in the patient’s serum before, during and after CPB  
• describe serial antibiotic levels in the circuits during the CPB period. 
The secondary objective of this study was to describe the pre-operative and intra-operative 
creatinine clearance. 
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3.4 Ethical considerations  
Approval to conduct this study was obtained from the Human Research Ethics Committee 
(Medical) (Appendix A) and the Postgraduate Studies Committee (Appendix B) of the 
University of the Witwatersrand. Written permission was obtained from the Chief 
Executive Officer of CMJAH (Appendix C). A change of title of the research report was 
approved from the Postgraduate Studies Committee (Appendix D). 
Participants were approached the day before surgery and the researcher explained the 
study and invited them to take part. If they agreed, they received a study information letter 
and were asked to give written consent (Appendix E).  
In order to maintain anonymity of the participants, their names or hospital numbers were 
delinked from the data capture sheets and the sample labels. Each participant was 
allocated a study number. Only the researcher had the information that links the 
participants name with the study number. This was kept in a separate file. Confidentiality 
was maintained as the researchers were the only people with access to the raw data.  
Each participant had blood samples taken on a regular basis intra-operatively. To reduce 
the amount of blood sampled, the blood was collected in micro-tubes so that each sample 
did not exceed 2 ml. This amounted to a maximum of 50 ml being sampled per patient. 
Sampling would continue for up to five hours or until surgery ended, whichever came first 
and in the latter case sampling was reduced. Additionally the patient was under 
anaesthesia and the blood sampling did not involve venepuncture but the use of indwelling 
arterial or venous catheters (placed as per standard surgical requirements and not for study 
purposes). One sample was taken when the patient was awake and this sample was taken 
from the intravenous drip site when it was inserted by the anaesthetist.  
The study records will be stored securely for six years following completion of the study.  
The study was conducted in adherence to the principles of the Declaration of Helsinki, 2013 
(19) and the South African Good Clinical Practice Guidelines (20). 
 
3.5 Research methodology  
3.5.1 Research design  
 A prospective, contextual, descriptive research design was used in this study.  
Cefazolin plasma concentrations were analysed at specific pre-determined time intervals 
in adults patients scheduled for elective valve replacement surgery and there was no 
randomisation. 
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3.5.2 Study population  
The study population comprised patients undergoing elective valve replacement, on CPB 
from the cardiothoracic unit at CMJAH. 
 
3.5.3 Study sample 
Sample size  
Given that this was not an interventional study, a traditional sample size calculation was 
not possible. Based from the experience of the BTCCRC research group in conducting 
multiple similar studies, enrolling 12 patients with rich pharmacokinetic sampling will 
enable a reasonably accurate description of relevant pharmacokinetic parameters in the 
study population. This chosen sample size is supported by the published literature as well 
as the following peri-operative pharmacokinetic studies being conducted with antibiotics 
with similar characteristics to cefazolin, or studies being conducted with cefazolin. The 
sample size in these pharmacokinetic studies range between 6 and 20, Douglas et al (74) 
n=12, Naik et al (75) n=16, Elkomy et al (56) n=20 and Bertholee et al (65) n=17. This sample 
size is likely to have sufficient power to identify the most important covariates which are 
associated with pharmacokinetic variability. However, we realised that the surgeon in our 
cardiothoracic unit, had a practice of requesting the valve to be dipped in a specific 
antibiotic of choice prior to surgical implantation. When this came to our attention, after 
consulting with the BTCCRC research group and the ethics department of the university 
(Appendix F), we decided to increase the sample size to 16 patients. We then had 8 patients 
with valves dipped in cefazolin and the remainder dipped in gentamicin. Based on the 
results of this study, we would be able to derive a sample size calculation for any future 
interventional study.  
Sampling Method  
The process of selecting a group of individuals from a population, to accurately represent 
the population, forms the basis of a sampling method (76). In this study, the sampling 
method used was convenience sampling, which is detailed by Burns and Grove (76) as 
choosing available subjects for the study until an adequate sample size is reached.  
Inclusion and exclusion criteria 
Inclusion criteria for this study were: 
• adult patients, aged between 18 and 60 years  
• undergoing elective valve replacement surgery  
• consenting to participate in the study. 
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Exclusion criteria for this study included:  
• Jehovah’s Witness  
• pregnancy  
• receiving dialysis  
• septic shock 
• emergency cases 
• receipt of cefazolin in the last 72 hours  
• deviation from the standard antibiotic protocol. 
 
3.5.4 Data collection  
This research project was a collaborative project between the CMJAH research group and 
the BTCCRC. This research report only addresses three objectives of the larger study 
therefore the data collection reflected more data than were necessary to answer these 
objectives. 
Discussion of the data collection process include the data collector, data collection period 
and data collected with the process of collection. 
Data was collected by one researcher (DC) from the CMJAH research group. All the 
members had an in depth knowledge of the data collection procedure to ensure 
standardised collection of data should the researcher not have been available. 
Data was collected between 11 November 2014 and 26 March 2015. 
The process of data collection is shown in Table 3.1. 
Table 3.1 Data collected with the process of collection 
Data Collection Standard operating procedure  
Invite patient Participants were approached the day 
before surgery and the researcher 
explained the study and invited them to 
take part 
If they agreed, they received a study 
information letter and were asked to give 
written consent 
Antibiotic prophylaxis  
• cefazolin 2 g IV within before 30 
minutes surgical incision  
• repeat 2g IV dose intra-operatively 
if >4 hours 
 
2 g of cefazolin was diluted in 20 ml saline 
and given intravenously over 5 minutes 
34 
 
Blood Samples 
Pre-operative bloods 
• routine albumin, Urea and 
electrolytes (U&E) 
Intra-operative bloods  
 
Pharmacokinetic bloods 
Venous sampling 
• pre antibiotic administration (from 
IV line insertion site) 30 minutes 
before incision 
• from the central venous catheter 
(CVC) at time 2, 5, 10, 30, 60, 90, 
120, 150, 180, 210, 240, 270 and 
300 minutes 
• CVC blood sampling at 5 minutes 
before and 5 minutes after CBP is 
initiated 
• CVC blood sample 5 minutes after 
CPB is completed 
  
Arterial sampling from CPB circuit 
• 5 mins after going on CPB 
• sample 2-6 to correspond with 
venous samplings 
1. Pre-operative bloods and intra-
operative U&E were tested at the 
National Health Laboratory Service 
2. Pharmacokinetic blood samples 
were restricted for the duration of 
the surgery, e.g. meaning if the 
surgery was completed at 180 
minutes then the blood sampling 
was be aborted 
3. CVC and CPB samples were taken 
simultaneously each time a CVC 
sample is taken in point. This did 
not exceed 7 samples 
4. CVC samples were taken in the 
following manner 
• 20 ml aspirated from the 
CVC line 
• a 2 ml volume was sampled 
in a yellow top microtube 
• 20 ml aspirate replaced 
• Microtube was labelled 
with a pre-printed self-
adhesive label 
5. CPB samples were taken in the 
following manner 
• were taken from the 
arterial port of the CPB 
circuit 
• a 2 ml sample was taken in 
a yellow top microtube 
• microtube was labelled with 
a pre-printed self-adhesive 
label 
6. All blood sample were centrifuged  
• within minutes 
• centrifuged in theatre (one 
standard machine) 
• at 3000rpm for 10 minutes 
• the plasma was then 
transferred to a microtube 
with a disposable pipette 
• the microtube was labelled 
with a pre-printed self-
adhesive label 
7. Storage of blood sample:  
•  In a -80°C freezer 
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• In the Department of 
Medicine 
o continuous 
temperature 
monitoring 
o with back-up CO2 
o back-up power from 
the hospital 
generator 
8. Courier of sample 
• all blood sample were 
couriered at study 
completion 
• by a courier, which 
specialises in transport of 
research sample 
9. Sample analysis 
• sample were analysed at 
the BTCCRC 
• accredited laboratory                                                         
Urine sample 
• collected at time of urine catheter 
insertion 
• repeated at post-surgery 
completion 
 
 
• 10 ml was be collected 
• labelled with a pre-printed self-
adhesive label 
• stored same as blood samples 
• couriered same as blood sample 
• analysed same as blood sample 
  
No patients required snaring in this study, therefore blood was available from the CVC. 
Should any patients have required snaring, the surgeon would have been requested to 
intermittently release the snare to allow blood sample to be collected from the CVC. 
 
Data collected 
The following additional data were also collected on the data collection sheet (Appendix 
G): 
• demographic data (gender, age, date of surgery, height, weight, APACHE II score, 
renal function and albumin) 
• pre-operative antibiotics 
• anaesthetic agents used 
• intra-operative fluids, including blood products 
• CPB time 
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• cross-clamp time 
•  vasopressor used 
• Intra-operative complications 
• duration in theatre. 
 
3.5.5 Sample analysis 
All blood samples were centrifuged after acquisition. Plasma was pipetted into 
appropriately labelled microtubes. The plasma and urine microtubes were stored at -80 ˚C. 
An export permit was obtained from the Department of Health, South Africa (Appendix H) 
and on completion of sample collection the samples were couriered on dry ice, in a 
temperature controlled container by a specialised medical specimen transport company to 
the BTCCRC for analysis. Ultra-high-performance liquid chromatography-tandem mass 
spectrometry was employed to analyse the study samples (77).  
 
3.5.6 Data analysis  
Data was captured and analysed on a Microsoft® Excel 2013 spreadsheet. Descriptive and 
inferential statistics was used. Categorical variables were described using frequencies and 
percentages, continuous variables were described using means and standard deviations. 
Time series analysis of the serum samples was done by the bio-statistician involved in the 
research group in Australia. This analysis was sent to the researcher for interpretation for 
this MMed project. A Kaplan-Meier curve was used to graphically display the serum 
samples. Paired T tests were used to compare both the pre-operative and intra-operative 
creatinine clearance and the arterial and corresponding venous samples on CPB. A p value 
of < 0.05 was considered statistically significant. 
 
3.6 Reliability and validity  
Bothma et al (78) defined validity of the study as “ the degree to which measurement 
represents the true value” and reliability as ”the consistency of the measure achieved”.  
The reliability and validity of this study was maintained by: 
• using an appropriate study design and data capturing technique 
• adhering strictly to the standard operating procedure for data collection 
• collection of data by only one researcher (DC) 
• storing specimen in a quality controlled -80 °C freezer 
• using a courier service specialising in the transport of research samples 
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• analysing bloods and samples in an accredited facility 
• analysing data using appropriate statistical methods in consultation with the 
biostatistician. 
 
3.7 Summary 
In this chapter the research methodology was described in details. In the following chapter 
the results and discussion will be presented. 
  
38 
 
Chapter 4: Results and discussion 
 
4.1 Introduction 
This chapter contains the results and discussion. The results are presented in accordance 
with the objectives of the study. 
The primary objectives of this study were to:  
• describe antibiotic levels in the patient’s serum before, during and after CPB  
• describe serial antibiotic levels in the circuits during the CPB period. 
The secondary objective of this study was to describe the pre-operative and intra-operative 
creatinine clearance. 
 
4.2 Sample realisation 
A sample size of 16 patients was determined in consultation with the BTCCRC. Sixteen 
patients were enrolled from 11 November 2014 until 26 March 2015 and there were no 
exclusions. 
 
4.3 Results 
4.3.1 Patient demographics 
The sixteen patients included comprised an equal number of males and females. 
The patients’ demographics are shown in Table 4.1. 
Table 4.1 Patient demographics 
Demographics Mean (SD) Minimum Maximum 
Age (years) 
Height (cm) 
Weight (kg) 
BMI (kg/m2) 
APACHE II 
Onset of CPB, from initiation of 
infusion of cefazolin (minutes) 
Mean CPB time (minutes) 
44 (11.98) 
163.88 (9.98) 
75.06 (15.55) 
28.22 (6.72) 
16.63 (2.58) 
71 (17.20) 
 
180 (55.41) 
18 
144 
51 
18.1 
12 
44 
 
105 
59 
180 
97 
40.2 
21 
102 
 
279 
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4.3.2 Objective: describe antibiotic levels in the patients’ serum before, during and after 
CPB  
Table 4.2 shows the total cefazolin serum levels of the 16 patients during cardiac valve 
surgery on CPB. 
 
Table 4.2 Total cefazolin serum level (µg/ml) during CPB surgery 
      First dose of cefazolin                                                                                                   Second dose of cefazolin 
                   ↓                                                                                                                   ↓ 
Patient Bld 1 Bld 2 Bld 3  Bld 4 Bld 5 Bld 6 Bld 7 Bld 8 Bld 9 Bld 10 Bld 11 Bld 12 Bld 13 Bld 14 
1 0 398.33 272.82 197.43 156.44 126.46 67.02 58.30 54.51 52.12 45.04 39.14 170.59   
2 0 344.84 288.91 241.33 185.28 113.19 97.37 99.68 83.16 74.43 70.90       
3 0 349.34 331.18 271.92 224.39 95.95 84.05 82.101 73.71 59.81 49.77 43.22 163.38 130.01 
4 0 301.43 248.37 214.88 156.63 86.94 73.80 61.15 55.43 50.93 43.49 40.22 192.49   
5 122.87 378.30 257.37 155.8 117.47 86.22 70.69 64.00 53.96 42.84 34.15 27.86 154.97   
6 0 274.72 248.47 213.98 159.71 93.59 75.73 64.03 65.16 60.46 55.97 48.36 163.36 138.60 
7 0 256.54 235.82 202.36 151.59 120.25 69.3 63.42 54.1 31.88 34.18 35.13     
8 0 336.14 294.37 236.75 157.51 123.04 71.62 70.53 61.44 48.84 43.39 41.73     
9 0 186.26 152.42 123.88 80.23 61.15 51.27 48.43 40.41 34.92 33.78 31.56 120.36 86.67 
10 0 334.60 313.16 266.26 209.37 162.79 105.35 92.77 86.62 71.24 62.03 57.57     
11 0 319.27 212.66 168.65 134.95 98.05 87.50 79.11 76.43 76.14 83.40 69.76 182.85 148.80 
12 0 338.52 248.97 199.66 147.44 124.45 107.23 107.99 108.58 111.93 107.94 103.51 234.78 212.19 
13 0 320.32 252.93 202.19 148.16 116.39 62.51 62.71 61.12 52.51 61.29 49.42 169.77   
14 0 324.61 282.98 235.53 170.08 127.54 80.73 74.74 77.00 82.76 79.71 66.3 145.55 125.55 
15 0 270.34 219.54 199.26 147.93 113.92 87.45 50.32 45.01 42.5 32.54 32.12 142.52 96.42 
16 0 335.87 295.45 226.68 195.10 140.81 86.36 73.56 65.26 87.42 67.82 66.80 191.57 164.38 
Mean 7.68 316.84 259.71 209.79 158.89 111.92 79.87 72.05 66.37 61.30 56.59 50.18 169.35 137.83 
SD 30.72 50.81 43.47 38.50 34.53 24.36 15.24 16.88 17.30 21.42 21.45 19.93 29.32 39.46 
 
Bld = Blood sample. 
 
Blood 1 of all the patients, except patient 5, was taken prior to initiating the cefazolin 
infusion and had no time factor to it. The subsequent bloods were all sampled timeously 
as per protocol, i.e time 2, 5, 10, 30 minutes, etc. With regard to patient 5, the patient had 
difficult intravenous access resulting in a delay in setting up invasive lines (arterial line and 
CVP catheter), hence the antibiotic infusion was started without any further delay (ensuring 
that it was started 30 minutes prior to incision time) and blood 1 was obtained 
simultaneously. This lead to an erroneous value in blood 1 of patient 5, as the actual value 
should have been 0 µg/ml. The subsequent bloods of patient 5 were sampled timeously. 
 CPB 
 Sub-therapeutic 
level 
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Therefore, the decision was made not to exclude patient 5 from the study as there was no 
actual deviation from the standard antibiotic protocol.  
A centre specific practice by the surgeon in our cardiothoracic unit is to request the valve 
to be dipped in an antibiotic of choice prior to surgical implantation. When this came to our 
attention we decided to increase our sample size from 12 to 16 patients (with relevant 
ethics approval, Appendix F). Half of the patients had their valves dipped in cefazolin and 
the other 8 patients’ valves were dipped in gentamicin prior to implantation. Of note, 
patient number 1, 2 and 11-16 had their valves dipped in cefazolin. 
The measured total antibiotic concentration is the sum of the free antibiotic concentration 
(unbound) and the bound antibiotic concentration. The bound cefazolin concentration 
depends on plasma protein binding which has a range of 75% to 90% in the literature (55, 
56, 68, 70, 73). In this study, based on the expertise of the BTCCRC group, the maximum 
protein binding value was used and hence a free level of 10% was calculated from the 
measured total cefazolin level. The unbound level has more clinical significance as it needs 
to correlate with the MIC of the relevant pathogens. The mean free cefazolin serum level 
is graphically represented in Figure 4.1. 
 
 
Figure 4.1 Mean free cefazolin serum concentration  
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The mean value of the trough from Figure 4.1 for the unbound concentration time curve 
was 5.02 µg/ml with a range of 2.79 to 10.35 µg/ml. According to the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) database from the European Society of 
Clinical Microbiology and Infectious Diseases, a value of 4 µg/ml and above of unbound 
cefazolin would be therapeutic against the common pathogens (73, 79). However, we 
found that this MIC level was not achieved in 5 out of the 16 patients (31.25 %) throughout 
surgery namely patient 1, 5, 7, 9 and 15. The Kaplan-Meier survival curve depicts this in 
Figure 4.2 below. Of note, patient 1 and 15 had their valves dipped in cefazolin and patients 
5, 7 and 9 had their valves dipped in gentamicin. 
 
 
Figure 4.2 Kaplan-Meier survival curve for cefazolin concentration greater than 4µg/ml 
 
4.3.3 Objective: describe serial antibiotic levels in the circuits during the CPB period 
At the initiation of CPB a blood sample was taken from the arterial port of the CPB circuit 
and simultaneously a venous sample was withdrawn from the CVP. Following this, the 
arterial samples were taken simultaneously with the corresponding venous sample every 
30 minutes as per the protocol. 
The measured total cefazolin concentration is represented in Table 4.3 and graphically 
shown in Figure 4.3. 
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Table 4.3 Cefazolin serum level (µg/ml) of arterial and corresponding venous sample on 
CPB 
Pt.  Art1 Ven Art 2 Ven Art 3 Ven Art 4 Ven Art 5 Ven Art 6 Ven Art 7 Ven 
1 74.09 70.70 65.24 67.02 58.94 58.30 54.12 54.51 53.37 52.12 
    
2 119.90 122.17 117.45 113.19 97.30 97.37 94.61 99.68 78.05 83.16 73.483 74.43 
  
3 96.28 96.33 101.15 95.95 85.32 84.05 82.87 82.10 75.89 73.71 60.274 59.81 
  
4 91.58 129.52 82.84 86.94 72.76 73.80 58.33 61.15 53.79 54.43 49.824 50.93 41.65 43.49 
5 66.09 70.69 65.38 64.00 60.50 53.96 52.85 42.84 40.49 34.15 
    
6 81.64 81.77 72.61 75.73 61.95 64.03 62.02 65.16 59.38 60.46 54.89 55.97 46.16 48.36 
7 71.55 72.72 72.29 69.30 65.93 63.42 53.29 54.10 46.58 31.88 33.37 34.18 
  
8 69.95 68.07 71.40 71.62 67.36 70.53 59.60 61.44 34.77 48.84 
    
9 47.83 49.32 48.85 51.27 47.45 48.43 42.06 40.41 36.56 34.92 32.45 33.78 29.81 31.56 
10 103.89 151.55 103.56 105.35 91.70 92.77 91.57 86.62 71.43 71.24 
    
11 96.16 93.49 84.07 87.50 76.35 79.11 74.18 76.42 75.42 76.14 82.91 83.39 58.15 69.76 
12 130.27 130.42 103.20 107.99 102.87 108.58 106.98 111.90 109.77 107.94 97.85 103.51 229.45 234.77 
13 61.77 62.07 66.22 62.71 61.69 61.12 60.76 52.51 58.14 61.29 
    
14 73.36 72.16 76.30 80.73 76.31 74.74 178.31 77.00 80.06 82.76 77.70 79.71 63.88 66.30 
15 49.10 55.66 50.89 50.32 41.55 45.01 42.18 42.50 32.87 32.54 
    
16 89.18 95.40 80.91 86.36 72.16 73.56 65.40 65.26 85.97 87.42 66.83 67.82 65.02 67.82 
Mean 82.66 88.88 78.90 79.75 71.26 71.80 73.69 67.10 62.03 62.06 62.96 64.35 76.30 80.29 
SD 23.22 30.12 19.30 19.25 16.90 17.66 33.59 20.63 21.61 22.62 21.11 22.01 68.72 69.61 
 
Pt = Patient, Art = Arterial blood (From Arterial port of CPB circuit), Ven = Corresponding blood from the CVP 
(From Blood 1-14) and Sub-therapeutic levels highlighted. 
 
 
Figure 4.3 Mean total serum cefazolin concentration of arterial and venous samples 
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The arterial and corresponding venous samples were analysed using the paired t-test. 
There were no statistical differences between the arterial samples A1-A5 with their 
corresponding venous samples (p = 0.11, 0.34, 0.46, 0.32 and 0.98 respectively). However, 
there was a statistically significant difference between the arterial samples A6 and A7 and 
their corresponding venous samples (p = 0.024 and 0.025). 
 
4.3.4 Secondary objective: Describe the pre-operative and intra-operative creatinine 
clearance 
The patients’ pre-operative creatinine clearance as calculated by the Cockcroft-Gault 
formula as well as their intra-operative measured creatinine clearance are shown in Table 
4.4. As the pre-operative creatinine clearance was calculated, the values were rounded off 
to whole numbers. 
 
Table 4.4 Patients’ pre-operative and intra-operative creatinine clearance 
Patient 
number 
Pre-operative 
creatinine 
clearance (ml/min) 
Intra-operative 
creatinine 
clearance (ml/min) 
1 129 62.8 
2 63 52.1 
3 52 26.9 
4 145 186 
5 132 79.3 
6 54 111.1 
7 111 102.4 
8 114 174.7 
9 152 114.3 
10 98 52.6 
11 89 81.8 
12 114 77.1 
14 58 139 
15 103 124.9 
16 110 71.1 
Mean (SD) 101.6 (32.6) 97.1 (45.3) 
 
The urine sample of patient 13 was accidentally discarded by the laboratory technician, 
explaining why patient number 13 was removed from the urinalysis.  
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4.4 Discussion 
The pharmacokinetics of cefazolin on CPB had not previously been investigated at CMJAH. 
A few studies have investigated the cefazolin level on CPB namely Fellinger et al (16), 
Hutschala et al (3) and Adembri et al (15). However their results cannot be extrapolated to 
our patients as their dosing regimens were different. Hutschala et al (3) used a substantially 
higher dose of cefazolin which is not based from any national or international guidelines. 
The consequences of providing a sub-therapeutic level of prophylactic antibiotics in this 
population group carries an increased risk of morbidity and mortality peri-operatively. 
There is a gap in the literature concerning the pharmacokinetics of prophylactic antibiotics 
within the physiology of CPB. 
In our study, the total level of cefazolin was measured from all the blood samples that were 
collected. The total concentration is the sum of the bound concentration and the unbound 
or free concentration. The percentage binding of cefazolin (ranging from 75% to 90% in 
vivo studies) was estimated to be 90%, leaving a free fraction of 0.10 (10%) of the total 
concentration (55, 56, 73).  
Miller et al (63) described a decrease in total body clearance of cefazolin during CPB 
compared to pre-operative and post-operative clearance. This was primarily accounted for 
by a decrease in renal clearance, since cefazolin is primarily excreted unchanged by the 
kidneys. There findings were in contrast to what we observed amongst our patients. The 
calculated mean pre-operative creatinine clearance was 101.6 ml/min (SD 32.6) with a 
range of 52 to 152 ml/min whereas the measured intra-operative mean creatinine 
clearance was 97.1 ml/min (SD 45.3) with a range of 26.9 to 186 ml/min and there was no 
statistically significant difference between the two sets of data (p = 0.71). This finding could 
be explained by the opposing effects that occur with renal clearance during surgery. The 
typical decrease in renal clearance on CPB as described by Miller et al (63) with the 
opposing effect of augmented renal clearance seen both in SIRS (57) and in patients 
undergoing abdominal and trauma surgery (60) resulted in an unaltered creatinine 
clearance. 
The CPB time varied between patients with a mean of 180 minutes (SD 55.41), ranging from 
105 to 279 minutes. The onset of CPB from the initial antibiotic infusion also had wide 
variation with a mean of 71 minutes (SD 17.20), ranging from 44 to 102 minutes. This may 
be due to CMJAH being an academic institution. Clinicians with varying degree of 
experience ranging from junior registrars to senior consultants are involved with the cases 
while teaching concurrently. 
Based on the review article of Mets (17), we expected “a ‘break’ or ‘discontinuity’ in their 
plasma decay profile with the onset of bypass, with a sudden decrease in concentration” 
but the graphs of both the total and unbound level of cefazolin represented in Figure 4.1 
follows a three compartment model as previously discussed in Chapter 2, Figure 2.6. Hence, 
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a three-compartment linear model best described the time-course of the 211 total serum 
concentrations collected in this study before, during and after CPB. This model included 
zero order input of drug into the central compartment as depicted in Figure 4.4. 
 
 
 
 
   ktc                                                                  
                                    
 
 
 
Figure 4.4 Structural pharmacokinetic model for cefazolin in CBP surgical patients (73) 
Cl – Clearance; Vc –volume of the dosing compartment; Vt – volume of unbound drug compartment; kcp – 
rate constant for drug distribution from the central to peripheral compartment; kpc – rate constant for drug 
distribution from the peripheral to central compartment; kct – rate constant for drug distribution from the 
central to unbound drug compartment; ktc – rate constant for drug distribution from the unbound drug to 
central compartment. 
 
Cefazolin being a β-lactam antibiotic exhibits time dependant killing with very little post-
antibiotic effect. Thus to ensure adequate surgical prophylaxis the time above the MIC 
(T>MIC) should ideally be 100% of the dosing interval i.e. T>MIC should be achieved for 
the full surgical duration. With regards to the pathogens involved in SSIs, Staphylococcus 
aureus, coagulase-negative Staphylococcus aureus (Staphylococcus epidermidis), 
Escherichia coli and Enterobacter account for over 90% of the pathogens involved in SSIs 
(3, 4, 6, 30, 35, 42). Therefore an MIC of cefazolin suitable for these common pathogens 
should be attained throughout the surgical time. Based on the EUCAST database a value 
of 4 µg/ml would be effective prophylaxis against these pathogens (73, 79). 
Our observation was that this MIC level was not attained in 5 out of the 16 patients (31.25 
%) throughout surgery namely subject 1, 5, 7, 9 and 15. Furthermore subjects 7 and 9 
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demonstrated significant sub-therapeutic levels as early as 180 minutes from the initial 
infusion. Our current antibiotic regimen provided adequate antibiotic therapeutic levels to 
only 68.75% as depicted in the Figure 4.2. This is concerning for our population group since 
the occurrence of SSIs in the face of cardiac surgery can have drastic consequences on 
morbidity and mortality. These five subjects comprising of two males and three females 
had BMIs ranging from 21.2 to 29.8 with a mean of 25.08, which was less than the mean of 
the sample group 28.22. This indicates that the cause for their lower levels might be of an 
external nature. The remaining patients had antibiotic levels above MIC throughout the 
surgical time. In five patients the cefazolin levels of blood sample 12 taken four hours post 
initial infusion did approach MIC of 4 µg/ml. This only increased after a re-dose of two 
grams of cefazolin maintaining therapeutic levels in subsequent bloods sampled. This lends 
credibility to the theory that a re-dose is necessary after two t½ of the antibiotic. 
With regards to the CPB circuit, in his review article titled “The pharmacokinetics of 
anaesthetic drugs and adjuvants during cardiopulmonary bypass” Mets (17) details the 
anaesthetics drugs that are sequestered in the oxygenator circuit. The author mainly found 
lipophilic drugs such as opioids to be highly sequestered. With the onset of CPB the plasma 
concentration of these opioids dropped significantly by up to 55%. He also explained that 
the degree of sequestration is proportional to the lipid solubility of the opioid. In contrast, 
cefazolin being a hydrophilic drug was not sequestered in the circuit but instead showed a 
discontinuity in the decay profile at the onset of CPB followed by a slight rise in plasma 
concentration then the normal decay curve. 
While performing serial samples of both arterial (post CPB) and corresponding venous (pre 
CPB) blood on CPB we have been able to assess the degree of sequestration in the CPB 
circuit. The data is graphically represented in Figure 4.3. There was no statistically 
significant differences between the arterial samples A1 to A5 with their corresponding 
venous samples (p > 0.05). There was a statistically significant difference with the arterial 
samples A6 and A7 with their corresponding venous samples (p < 0.05). The clinical 
significance however of these differences is questionable. These findings point towards no 
sequestration in the CPB circuit, which is in line with the findings of Mets (17) in his review 
article. 
 
4.5 Summary 
In this chapter the results of the study as defined by the objectives were presented 
followed by a discussion of the results.  In the following chapter a brief summary will be 
presented followed by limitations, recommendations and finally the conclusion. 
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Chapter 5: Summary, limitations, 
recommendations and conclusions 
 
5.1 Introduction 
In this chapter a summary of the study method and results will be briefly reviewed, the 
limitations of the study will be addressed, recommendations made and a conclusion 
presented. 
 
5.2 Summary of the study 
5.2.1 Aim 
The aim of this study was to describe the total serum cefazolin levels during elective valve 
replacement surgery on CPB at CMJAH. 
5.2.2 Objectives 
The primary objectives of this study were to:  
• describe antibiotic levels in the patient’s serum before, during and after CPB  
• describe serial antibiotic levels in the circuits during the CPB period. 
The secondary objective of this study was to describe the pre-operative and intra-operative 
creatinine clearance. 
 
5.2.3 Methodology 
A prospective, contextual, descriptive design was used in this study. Cefazolin plasma 
concentrations were analysed at specific pre-determined time intervals in adults patients 
scheduled for elective valve replacement surgery at CMJAH. A sample size of 16 patients 
was determined based on the experience of the BTCCRC research group in conducting 
multiple similar studies. A convenience sampling method was used. The inclusion criteria 
for this study were consenting adults between 18 and 60 years, undergoing elective valve 
replacement surgery. The exclusion criteria for this study included Jehovah’s Witness, 
pregnancy, receiving dialysis, septic shock, emergency cases, cefazolin use in the last 72 
hours and deviation from the standard antibiotic protocol. 
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5.2.4 Results 
Even with the addition of the CPB circuit the decay profile of cefazolin followed a three 
compartment linear model with no discontinuity or sudden decrease in plasma 
concentration at the onset of CPB, but instead had slow decline in plasma concentration 
over time on CPB. The decline was substantial and sub-optimal in 31.25% of the patients at 
some point during their surgery leaving them, at times, with inadequate antibiotic levels 
for surgical prophylaxis. No significant cefazolin sequestration was found on the CPB circuit 
since there was no statistically significant difference between the pre and post CPB samples 
A1-A5 (p > 0.05). There was a statistically significant difference with the samples A6 and A7 
(p < 0.05), however the clinical significance of this remains questionable. Similar findings 
were shown for hydrophilic drugs by Mets (17). There was no statistically significant 
difference between the pre-operative creatinine clearance and the intra-operative 
creatinine clearance, contrasting to the findings of Miller et al (63).   
 
5.3 Limitations 
The assumption that the percentage protein binding of cefazolin remains constant 
throughout CPB surgery is a limitation. With the acute haemodilution experienced at the 
onset of bypass, due to the priming solution used on the CPB circuit, we would expect a 
change in percentage protein binding. For a drug that has a high plasma protein binding, 
haemodilution from the blood/prime mixture might result in a relatively larger increase in 
free fraction (17). Additionally, with the effect of heparin which results in the release of 
lipoprotein lipase hydrolysing plasma triglycerides into fatty acids that eventually 
competitively binds to plasma protein leading to a potentially higher free level of cefazolin.  
A change or a lower protein binding of cefazolin during CPB could be expected to be seen 
(17).  
 
5.4 Recommendations for clinical practice and future research 
The observation that potentially 31.25% of patients had sub-optimal protection in this 
study is concerning. We thus recommend that we follow with a larger, adequately powered 
study in order to ascertain if this observation is significant or not. And secondly, the 
assumption that the protein binding capacity of cefazolin remains constant throughout a 
surgical procedure where vast pharmacokinetic and physiological changes are expected to 
occur is a substantial limitation. Further analysis of the samples for the free plasma level 
would shed some light as to the exact free level concentration of the prophylactic 
antibiotics. 
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5.4 Conclusion 
SSIs have become the most common cause of nosocomial infections, not only significantly 
affecting morbidity and mortality rates but also placing further strain on the country’s 
economy. In cardiac surgery specifically, the risks associated with developing a SSI can 
quickly lead to the direst outcomes. This study has revealed that potentially 31.25% of the 
patients undergoing cardiac surgery may be at a higher risk of acquiring SSIs due to sub-
therapeutic dosing of prophylactic cefazolin being administered during surgery. In addition, 
the findings point towards no sequestration of cefazolin in the CPB circuits. 
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Appendix E: 
Information sheet and consent form for Study on cefazolin pharmacokinetics 
during CPB surgery. 
 
Hello, my name is Dr Daren Calleemalay. I am a medical doctor and I work in this hospital 
as an anaesthesiologist in training. I understand that you are going to have an operation 
soon to replace a valve. I would like to chat with you and invite you to take part in a study 
that is looking at what happens to the antibiotic that is given to you for the operation. 
For major operations like the one you are having, it is our practice to administer an antibiotic 
just before the surgeon starts to operate and then to continue for 24 hours thereafter. This 
is to prevent the occurrence of wound infections. The risk for a wound infection is 1-10%. 
In our hospital the risk is just under 5%. We would like to avoid such infections as they are 
associated with longer stays in hospital and a higher chance of patients not doing well. 
As your surgeon may have explained to you, during the procedure the blood that is returning 
to your heart and lungs will be diverted to a machine called the cardiopulmonary bypass 
(CPB) machine. This diversion will permit the surgeon to work on your heart. The machine 
also enriches your blood with oxygen as it is sent back to your body. 
What we do not know at the moment is, whether the CPB collects and retains some of the 
antibiotics, when your blood passes through the machine. If this is the case then it may 
mean that in future we may need to increase the amount of antibiotics we give when patients 
are attached to a CPB machine. 
We would thus like to ask you if you would be happy to participate in our study, which looks 
at the level of the antibiotic (that was given to you) that is retained in the CPB machine, your 
blood and your urine. This will help us determine if we need to change how we administer 
antibiotics in the future. Whilst the study may assist future patients it will not influence your 
management. I will also be using the results of this study to obtain an additional degree 
from the University of Witwatersrand (it is called a master in Medicine degree). 
If you participate we will take blood samples from you at different times whilst you are in 
theatre. The blood will be taken once when your drip is inserted for the operation and then 
when you are asleep. The total amount will not exceed 50 ml (5 tablespoons). Two samples 
of urine (2 tablespoons and part of the amount that is normally collected during the 
operation) will also be taken. The other tests are routine tests that you have before surgery. 
Your charts and theatre records will also be used. However no one will be able to identify 
you as your name will be removed. The samples will be stored in a fridge in this hospital (in 
a secure site with other samples for research) and then sent to Australia where it will be 
stored until it is analysed (the researchers from Australia are known to us). Once the testing 
is done the samples will be destroyed. 
It is your choice entirely-whether you wish to take part in this study. If you decide not to take 
part, that is perfectly fine and you will still get all the necessary treatment that you require. 
If you have any queries or concerns about this study you are most welcome to contact 
Professor Cleaton-Jones at 011-7171234. He is the Head of a committee called the Human 
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Research Ethics Committee that approved this study to happen. You may also contact 
Professor Fathima Paruk (one of the investigators) if you have queries about the study. Her 
number is 011-4884344. 
If you do choose to participate, I will ask you to indicate below that you have understood 
what I have told you and that you are willing to take part in this study. I will give you a copy 
of the information provided to you. Thank-you for listening to me. 
 
 
Consent form for study on cefazolin pharmacokinetics during cardiopulmonary 
bypass 
 
The doctor has explained the contents of the information leaflet (pertaining to the above 
study) and I have understood what he has discussed with me. 
I  …………………………………………… give consent ( provide permission) for myself to 
participate in the above study. 
 
 Name Signature Date 
Patient    
Researcher    
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Appendix G: 
Data sheet. 
Patient Initials  
Research Number  
Gender  
Age  
Date of Surgery  
Height  
Weight  
APACHE II  
Renal Function Urea                                        Creat 
Albumin   
 
PRE- OPERATIVE ANTIBIOTICS 
Antibiotic Name Dose Given Time Started Route 
    
    
    
 
ANAESTHETIC AGENTS USED 
Drug Name Total amount given 
  
  
  
  
  
  
ALL FLUIDS GIVEN IN THEATRE 
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Fluid Name 
Volume Given Time Given 
   
   
   
   
   
   
   
   
 
 
 
Total Volume of Fluids given Intra-operatively:  ___________ 
 
 
 
 
CEPHAZOLIN:  2 g diluted to 20ml of 0.9% saline and give over 5 min. 
 
 
 Blood (CVP)    
Enter OT    Venous  (CVP) SPECIFIC TIMING TO CPB 
IV access Tpreop 
(±30min 
before 
incision) 
Blood sample 
no. 1 
Time 
taken____ 
 Venous sample 
5minutes  before going ON  
CPB 
Venous sample 
no.1 
Time taken____ 
Induction Insert IDC 
and volume 
Urine Sample 
no. 1 
Time 
taken____ 
 Venous sample 5 minutes  
after  going  ON CPB 
Venous sample 
no.2 
Time taken____ 
Start of 
Surgery 
Antibiotic 
given 30 
  Venous sample 5 minutes 
5minutes after  coming OFF 
CPB 
Venous sample 
no.3 
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minutes pre-
incision 
Time taken____ 
       
 T=2min Blood sample 
no. 2  
Time 
taken____ 
 Arterial sample (from Circuit): WHEN ON 
CPB 
 T=5min Blood sample 
no.3 
Time 
taken____ 
 sample 5 minutes after  
going  ON CPB 
Arterial sample 
no. 1 
Time taken____ 
 T=10min Blood sample 
no. 4 
Time 
taken____ 
  When on CPB, take a 
specimen when blood is 
being sampled 
Arterial sample 
no. 2 
Time taken____ 
 T=30 min Blood sample 
no: 5 
Time 
taken____ 
 When on CPB, take a 
specimen when blood is 
being sampled 
Arterial sample 
no. 3 
Time taken____ 
 T=60min Blood sample 
no.6 
Time 
taken____ 
 When on CPB, take a 
specimen when blood is 
being sampled 
Arterial sample 
no. 4 
Time taken____ 
 T= 90min Blood sample 
no. 7 
Time 
taken____ 
 When on CPB, take a 
specimen when blood is 
being sampled 
Arterial sample 
no. 5 
Time taken____ 
 T= 120 min Blood sample 
no. 8 
Time 
taken____ 
 
 When on CPB, take a 
specimen when blood is 
being sampled 
Arterial sample 
no.6 
Time taken____ 
 T=  150 min Blood sample 
no. 9 
Time 
taken____ 
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 T=  180min Blood sample 
no. 10 
Time 
taken____ 
   
 T=  210min Blood sample 
no. 11 
Time 
taken____ 
   
REDOSE 
ANTIBIOTIC 
T=  240min Blood sample 
no. 12 
Time 
taken____ 
 
   
 T=  270min Blood sample 
no. 13 
Time 
taken____ 
   
 T=  300min Blood sample 
no. 14 
Time 
taken____ 
   
      
End of 
Surgery 
Empty IDC 
and volume 
Urine Sample 
no. 2 
Time 
taken____ 
   
 
 
 
 
ON CPB TIME ________ 
 
OFF CPP TIME ________ 
 
CROSS CLAMP ON TIME: ________ 
 
CROSS CLAMP OFF TIME: _________ 
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Surgical time interval   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
URINE COLLECTION  
Empty bag on arrival to ICU or when going to ward:  Leave bottle at bedside in ICU and place pink 
sticker on urine bag. 
 
 Start: _______        Stop: _______  U&E time (end of 4 hour collection): _________ 
 
 
 
Total Length of Time in OT: Start __________ Finish _________ 
 
 Details Time 
Induction    
Post Intubation   
CVL Insertion   
Incision   
X Clamp ON   
X Clamp OFF   
CPB ON   
CPB OFF   
Vaso-active   
Vaso-active   
Vaso-active   
Vaso-active   
ICU   
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Appendix H:  
 
  
